The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a `quality lead', where these `quality leads' come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.